on October 20, 2005
Published online before print October 20, 2005, doi: 10.1161/01.ATV.0000191663.12164.77
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 23, 2005
Accepted on October 12, 2005
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Florian Blaschke *;
From the Division of Endocrinology, Diabetes, and Hypertension (F.B., Y.T., E.C., W.A.H.), David Geffen School of Medicine, University of California, Los Angeles, Calif; the Department of Medicine/Cardiology (F.B.), German Heart Institute, Berlin, Germany; and the Department of Medical and Scientific Affairs (R.E.L.), Takeda Pharmaceuticals North America, Inc, Lincolnshire, Ill.
* To whom correspondence should be addressed. E-mail: fblaschke{at}mednet.ucla.edu.
Abstract--Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. The 3 PPAR isotypes, PPAR-
, PPAR-
, and PPAR-
, play a key role in the regulation of lipid and glucose metabolism. Obesity and the interrelated disorders of the metabolic syndrome have become a major worldwide health problem. In this review, we summarize the critical role of PPARs in regulating inflammation, lipoprotein metabolism, and glucose homeostasis and their potential implications for the treatment of obesity, diabetes, and atherosclerosis.
This article has been cited by other articles:
 |
|
 |
|
  F. Desjardins, B. Sekkali, W. Verreth, M. Pelat, D. De Keyzer, A. Mertens, G. Smith, M.-C. Herregods, P. Holvoet, and J.-L. Balligand Rosuvastatin increases vascular endothelial PPAR{gamma} expression and corrects blood pressure variability in obese dyslipidaemic mice Eur. Heart J., January 1, 2008; 29(1): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schindler Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Xu, S. R. Farmer, and B. D. Smith Peroxisome Proliferator-activated Receptor {gamma} Interacts with CIITA{middle dot}RFX5 Complex to Repress Type I Collagen Gene Expression J. Biol. Chem., September 7, 2007; 282(36): 26046 - 26056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Cha, X. Zhang, Y. Zhang, J. Wu, D. Su, J. Y. Han, X. Fang, B. Yu, M. D. Breyer, and Y. Guan Peroxisome Proliferator Activated Receptor {alpha}/{gamma} Dual Agonist Tesaglitazar Attenuates Diabetic Nephropathy in db/db Mice Diabetes, August 1, 2007; 56(8): 2036 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hiuge, A. Tenenbaum, N. Maeda, M. Benderly, M. Kumada, E. Z. Fisman, D. Tanne, Z. Matas, T. Hibuse, K. Fujita, et al. Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Giugliano and K. Esposito Optimal Treatments for the Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): e30 - e30. [Full Text] [PDF]
|
|